阳性判断标准：骨髓原始细胞≥0.20，CD38、HLA-DR均≥20%或CD3、cMPO≥10%，其他抗体≥20%。 根据CD34、CD123、CD38的表达情况，将164例AML患者分成阳性组与阴性组，并对两组的临床资料及骨髓细胞进行比较分析。

2021年11月11日 · As the transmembrane glycoprotein CD38 has been shown to regulate cytokine release, we assessed the anti-leukemic potential of CD38 inhibition in AML. CD38 expression in AML cells proved...

目的:分析急性髓系白血病 (AML)CD34、CD38抗原表达特点及临床意义.方法:采用单克隆抗体直接免疫荧光标记法的流式细胞术,对55例AML患者进行免疫表型检测.结果:AML患者CD34和CD38表达均达40.0%.AML CD34+患者完全缓解 (CR)率 (19.0%)明显低于CD34-患者 …

2021年11月11日 · CD38 expression in AML cells proved to depend on microenvironmental cues and could be significantly enforced through addition of tretinoin. In fact, the anti-CD38 antibody daratumumab showed significant cytostatic efficacy in a 3D in vitro triple-culture model of AML, but with modest cell-autonomous cytotoxic activity and independent of CD38 ...

Substances Antineoplastic Agents Membrane Glycoproteins CD38 protein, human ADP-ribosyl Cyclase 1

2021年11月5日 · Daratumumab is a therapeutic drug targeting CD38. It is widely used in myeloma, but it has not been applied in AML. The prognosis of 4 patients with acute myeloid leukemia treated with CD38 monoclonal antibody combined with demethylating drugs / traditional chemotherapy was reviewed.

2021年5月25日 · CD38 is known to be expressed on most AML and myeloma cells, and its lack of expression on hematopoietic stem cells (HSCs) renders it a potential therapeutic target for relapsed AML.

We first used flow cytometry to measure CD38 expression on leukemic blasts of 37 AML and 12 T-ALL patient samples taken at diagnosis. As shown, we observed a heterogeneous expression of CD38 in AML, while in T-ALL the expression of CD38 was more uniform (Figure 1A and B).

2024年4月18日 · The authors show that coculture of BN-CD38 with T cells and AML cell lines led to activation of T cells (via surface expression of CD69 and CD25), secretion of proinflammatory cytokines (including IFN-γ), and clearance of CD38 + cells.

2000年2月1日 · CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P <0.001), but was similar among ALL subtypes (56.6%; P …